Bio Usawa Inc.
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.7Mattributed |
|---|---|
| Latest round | Funding round, $1.7M, 2025-12-17attributed |
| Founded | unknown |
| Headquarters | SAN FRANCISCO, CA |
| Industry | bio |
| Stage | unknown |
| Website | biousawa.com |
Biosimilars and bio-better manufacturer based in Rwanda producing affordable monoclonal antibody therapies in oncology, ophthalmology and immunology. Serves African patients who currently lack access to anti-VEGF and similar therapies. Targets roughly one-tenth of US pricing through made-in-Africa manufacturing with local R&D talent.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-17 | Funding round | $1.7M | undisclosed |
Detected tech stack
Cloudflare, reCAPTCHA, Google Analytics, Google Tag Manager, Slick 1.8.1, jQuery CDN, jsDelivr, DoubleClick Floodlight, cdnjs, WordPress, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $1.7M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $1.7M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | biousawa.com, read 2026-05-05 |
| Description | self-reported | biousawa.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $1.7M, 2025-12-17 → Funding round, $1.7M, 2025-12-17, sec-edgar, No document URL on file | Latest round | seed, $1.7M, 2025-12-17 → Funding round, $1.7M, 2025-12-17 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes